Dupilumab (trade name: Dupixent) has been approved in Germany since September 2017 for the treatment of moderate to severe eczema in adults who are able to have treatment with tablets or injections (systemic treatment). As of August 2019, it is also approved for use in children aged 12 years and over under the same conditions.
Eczema – also known as atopic eczema or atopic dermatitis – is a chronic (long-lasting), non-infectious skin condition.
Typical symptoms include rashes and severe itching that come and go in episodes. The acute symptoms include red and itchy skin, sometimes with blisters that easily break and then weep (leak liquid). Over time the skin can become dry and cracked, and also thicken.
Treatment with dupilumab aims to decrease the inflammation in the skin by inhibiting a chemical messenger that causes inflammation.
Dupilumab is available as pre-filled syringes at doses of 200 or 300 mg.
Adults and teenagers with a body weight over 60 kg: The first time dupilumab is used, 600 mg of the medication is injected under the skin (two injections of 300 mg each). After that, one 300 mg injection is used every two weeks.
Teenagers with a body weight of less than 60 kg: At first, 400 mg of the medication is injected under the skin (two injections of 200 mg each). After that, one 200 mg injection is used every two weeks.
Patients can also inject themselves after being instructed how to do so by a doctor.
The effectiveness of the treatment needs to be assessed regularly. If there is no improvement after 16 weeks, doctors usually recommend stopping the treatment.
For people with moderate to severe eczema who are able to have systemic treatment, the standard approach is optimized individual treatment. This treatment will depend on various factors, including which treatments have been tried before. It is individually adjusted by the doctor. The medication options include tacrolimus, glucocorticoids (steroids used on the skin as a cream) and ciclosporin. In adults, UV light treatment or the systemic use of glucocorticoids are also options.
In 2018, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether dupilumab has any advantages or disadvantages compared to optimized individual treatment in adults with moderate to severe eczema.
In 2019, IQWiG looked into whether dupilumab has any advantages or disadvantages compared to optimized individual treatment for moderate to severe eczema in children aged 12 years and over.
This information summarizes the main results of reviews produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The reviews were commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.”
On the basis of the reviews and the hearings received, the G-BA passed a resolution on the added benefit of dupilumab (Dupixent) for teenagers and adults.
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Dupilumab (Atopic dermatitis) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A17-63. February 27, 2018. (IQWiG reports; Volume 601).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Dupilumab (Atopic dermatitis in adolescents) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A19-75. November 28, 2019. (IQWiG reports; Volume 847).
IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.
Comment on this page
What would you like to share with us?
We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.